RxDoctor Payments Data

Craig Badolato, MD

Hematology & Oncology · Melbourne, FLNPI 1013998970

Payments from drug & device makers

$42,100in general payments, 2019–2025

Across 1,720 payments — averaging $24.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Johnson & Johnson$3K
  • Novartis$2K
  • Incyte Corporation$2K
  • Pfizer$2K
  • Merck$2K
  • plus $25K from 54 others

What the payments were for

  • Consulting fees$5001%
  • Speaking & faculty fees$1,0002%
  • Food & beverage$39,46694%
  • Education$6352%
  • Other$4991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)121$3,822
Johnson & Johnson(2 entities)95$2,668
Novartis122$2,404
Incyte Corporation70$2,219
Pfizer164$2,126
Merck90$1,978
E.r. Squibb & Sons, L.L.C.66$1,815
Genentech USA, Inc.43$1,489
Bayer52$1,282
Daiichi Sankyo Inc.50$1,257
Sanofi48$1,087
Regeneron Healthcare Solutions, Inc.24$985
Takeda Pharmaceuticals U.S.A., Inc.24$981
Bristol Myers Squibb48$957
Seagen Inc.39$948
Astellas Pharma US Inc43$893
Lilly USA, LLC40$892
Puma Biotechnology, Inc.13$883
Eisai Inc.36$866
GSK33$859
Amgen37$707
AbbVie27$689
Gilead(2 entities)21$496
Pharmacyclics LLC, An Abbvie Company20$461
Ipsen Biopharmaceuticals, Inc17$434
Tolmar Pharmaceuticals, Inc.22$407
Novocure Inc.7$393
Jazz Pharmaceuticals Inc.16$387
Mirati Therapeutics, Inc.9$384
Boehringer Ingelheim16$376
Genmab U.S., Inc.6$346
Array Biopharma Inc11$327
Beigene USA, Inc.15$320
Karyopharm Therapeutics Inc.10$284
G1 Therapeutics, Inc.9$266
Dendreon Pharmaceuticals LLC5$255
Stemline Therapeutics Inc.11$254
Sobi, Inc10$229
EMD Serono, Inc.12$225
Taiho Oncology, Inc.13$223
Blueprint Medicines Corporation6$210
Servier Pharmaceuticals LLC9$198
Epizyme, Inc.4$169
Pharmacosmos Therapeutics Inc.8$167
Beone Medicines USA, Inc.8$166
Myriad Genetic Laboratories, Inc.8$159
Advanced Accelerator Applications3$146
Verastem, Inc.2$138
Sumitomo Pharma America, Inc.6$135
Clovis Oncology, Inc.10$130
Tersera Therapeutics LLC6$129
Rigel Pharmaceuticals, Inc.2$121
Pharmaessentia USA Corporation5$120
ADC Therapeutics America, Inc.6$109
Global Blood Therapeutics, Inc.6$108
Dova Pharmaceuticals7$92
Caris MPI, Inc.5$92
Agios Pharmaceuticals, Inc.5$84
Heron Therapeutics, Inc.5$84
Foundation Medicine, Inc.5$83

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,100 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$2,887,342
Medicare patients
381
Services billed
136,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide42$823,288
Lenalidomide42$616,654
XtandiEnzalutamide30$420,491
IbrancePalbociclib23$357,670
ImbruvicaIbrutinib24$352,800
SprycelDasatinib13$235,531
VenclextaVenetoclax13$189,839
PromactaEltrombopag Olamine14$184,109
EliquisApixaban44$33,225
XareltoRivaroxaban45$29,219
Imatinib Mesylate11$10,492
Enoxaparin Sodium23$3,595
Anastrozole123$2,640
Oxycodone Hcl74$2,322
Bicalutamide21$1,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$957$823,28842 claims
Astellas Pharma US IncXtandi$893$420,49130 claims
PfizerIbrance, Eliquis$2,126$390,89567 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$461$352,80024 claims
E.r. Squibb & Sons, L.L.C.Sprycel$1,815$235,53113 claims
AbbVieVenclexta$689$189,83913 claims
NovartisPromacta$2,404$184,10914 claims
Johnson & JohnsonXarelto$2,668$29,21945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →